This is a preview of subscription content, log in via an institution to check access.
Notes
incremental cost-effectiveness ratio
References
Durand-Zaleski I, et al. Application of New French Guidelines for Economic Evaluations: a Cost-Effectiveness Analysis of Apixaban in Patients with Non-Valvular Atrial Fibrillation in France. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCV67, 2 Nov 2013.
Kelly J, et al. The Cost-Effectiveness of Apixaban Compared to Warfarin, Aspirin, Rivaroxaban and Dabigatran in Ireland. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCV102, 2 Nov 2013.
Rights and permissions
About this article
Cite this article
Apixaban shines in France and Ireland. PharmacoEcon Outcomes News 692, 7 (2013). https://doi.org/10.1007/s40274-013-0890-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0890-8